Leuprorelin depot

Drug Profile

Leuprorelin depot

Alternative Names: Carcinil; Enanton Depot; Enanton-Gyn; Enantone; Enantone Depot; Enantone LP; Ginecrin; Leuplin; Leuplin SR; Leuprolide acetate depot; Leuprolide acetate for depot suspension; Leuprolide depot; leuprorelide for depot suspension; Leuprorelin acetate depot; Lucrin; Lucrin Depot; Lupron Depot; Lupron Depot-PED; Procren Depot; Procrin; Prostap SR; TAP-144-SR; Trenantone-Gyn

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Developer AbbVie; Norwood Abbey; Takeda
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Menorrhagia; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Discontinued Haematological disorders

Most Recent Events

  • 01 Nov 2016 Takeda completes a phase III trial in Prostate cancer (12-month formulation) in France (SC) (NCT02085252)
  • 15 Mar 2016 Biomarkers information updated
  • 15 Dec 2015 Launched for Breast cancer in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top